Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 6 years, Jamjoom Pharmaceuticals Factory Co's highest 3-Year average EPS without NRI Growth Rate was 36.60% per year. The lowest was 10.80% per year. And the median was 29.30% per year.
Jamjoom Pharmaceuticals Factory Co (SAU:4015) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Jamjoom Pharmaceuticals Factory Co EPS (Diluted) Related Terms
Jamjoom Pharmaceuticals Factory Co EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co EPS (Diluted) Chart
SAU:4015 vs ZTS, UTHR, VTRS: EPS (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jamjoom Pharmaceuticals Factory Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jamjoom Pharmaceuticals Factory Co PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jamjoom Pharmaceuticals Factory Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Jamjoom Pharmaceuticals Factory Co's PE Ratio falls into.
Jamjoom Pharmaceuticals Factory Co EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼6.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co (SAU:4015) has a EPS (Diluted) of ﷼6.79 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors.
Is Jamjoom Pharmaceuticals Factory Co's EPS (Diluted) too high?
Jamjoom Pharmaceuticals Factory Co's current EPS (Diluted) is ﷼6.79. Overall, Jamjoom Pharmaceuticals Factory Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jamjoom Pharmaceuticals Factory Co's EPS (Diluted) compare to ZTS and UTHR?
Jamjoom Pharmaceuticals Factory Co's EPS (Diluted) of ﷼6.79 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors. Jamjoom Pharmaceuticals Factory Co's current EPS (Diluted) is ﷼6.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jamjoom Pharmaceuticals Factory Co stock overvalued right now?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co (SAU:4015) is currently considered Modestly Undervalued. The stock's GF Value™ is ﷼182.59, compared to a current price of ﷼146.60 — trading 19.7% below its estimated fair value. The current EPS (Diluted) is ﷼6.79. Jamjoom Pharmaceuticals Factory Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Jamjoom Pharmaceuticals Factory Co (SAU:4015), the current EPS (Diluted) is ﷼6.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jamjoom Pharmaceuticals Factory Co (SAU:4015) Overvalued in 2026?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co stock appears to be undervalued.
The current stock price of ﷼146.60 is trading 19.7% below its estimated GF Value™ of ﷼182.59.
GuruFocus considers Jamjoom Pharmaceuticals Factory Co to be Modestly Undervalued.
Key valuation signals for SAU:4015:
EPS (Diluted): ﷼6.79
GF Value™: ﷼182.59 vs. price of ﷼146.60 (19.7% below fair value)
No single metric tells the full story. See the SAU:4015 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jamjoom Pharmaceuticals Factory Co Business Description
Jamjoom Pharmaceuticals Factory Co is engaged in producing human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer and acidity, treatment of various skin infections, cancer diseases, eye drops and ointments and cosmeceuticals. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
75GF Score
Get the complete analysis for SAU:4015
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4015 has been successfully added to your 
